Sector Chart Satellos Bioscience Inc.

Stocks

MSCL

CA80401L8033

Biotechnology & Medical Research

Delayed Toronto S.E. 18:24:36 09/09/2026 +03			5-day change	1st Jan Change
12.89 ^CAD	+0.94%		+3.17%	+64.14%

03:36pm	Satellos Bioscience Inc Announces Forazapadin As Assigned International Nonproprietary Name For Lead Drug Candidate SAT-3247	CI
08-14	Satellos Bioscience Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Sector Bio Therapeutic Drugs

	Capi.	Sales Growth	Profitability	Finances	EV / Sales	P/E
SATELLOS BIOSCIENCE INC.	197M	-	-	-	-	-
WUXI APPTEC CO., LTD.	69.19B
ARGENX SE	62.97B
INSMED INCORPORATED	27.27B					-
BIONTECH SE	24.78B					-
WUXI BIOLOGICS (CAYMAN) INC.	25.8B